Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
CY200 has FDA Orphan Drug Designation, and Ensysce submitted its Phase 2a study protocol to the UK regulator in September 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ensysce Biosciences (ENSC) announced that President James Morrison participated in the Family Office Summit in Dubai on October 15, 2026. He met family offices from across the Middle East to introduce the company's severe chronic pain focus and begin relationships with investors and potential partners. The company described the visit as part of its expanding global investor and strategic outreach.
In September 2026, Ensysce submitted a protocol for a Phase 2a study of CY200 for Complex Regional Pain Syndrome (CRPS) to the UK Medicines and Healthcare products Regulatory Agency. CY200 joined its pipeline through the August 2026 acquisition of Cy Biopharma and has received FDA Orphan Drug Designation. No therapy has been approved by the FDA for CRPS.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointCY200 Phase 2a study protocol for CRPS submitted to the UK regulator in September 2026.
- Moderate pointCy Biopharma acquisition in August 2026 added CY200 to Ensysce's clinical pipeline.
- Minor pointCY200 has received FDA Orphan Drug Designation for CRPS.
Negative
- None.
Details
Market Reaction – ENSC
On Oct 21, the day this news came out, the latest delayed price for ENSC is 0.70% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $0.50.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
complex regional pain syndrome medical
phase 2a medical
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS") today announced that James Morrison, President of Ensysce Biosciences, participated in the Family Office Summit, Dubai, on October 15, 2026.
The visit was a central component of Ensysce's expanding global investor and strategic outreach initiative. At the summit, a private gathering for the family office sector, Mr. Morrison met family offices from across the Middle East to introduce the Company and its focus on severe chronic pain, and to begin long-term relationships with investors and potential partners in the region.
The meetings came as Ensysce enters a pivotal period of corporate and clinical development. In September 2026, the Company submitted the protocol for a Phase 2a clinical study of CY200, its clinical-stage candidate for CRPS, to the UK Medicines and Healthcare products Regulatory Agency.
Following Ensysce's acquisition of Cy Biopharma in August 2026, CY200 has become a key component of the Company's growth strategy and clinical pipeline. CRPS is a severe and debilitating chronic pain disorder for which no therapy has been approved by the U.S. Food and Drug Administration ("FDA"). CY200 has received Orphan Drug Designation from the FDA.
"We are entering an important stage in Ensysce's evolution, and expanding our relationships with sophisticated global investors and strategic partners is a key priority," said James Morrison, President of Ensysce Biosciences. "The UAE has rapidly developed into a major international center for capital, healthcare innovation and life sciences, making this an ideal opportunity to tell the Ensysce story and introduce the Company to a broader global investment community."
Mr. Morrison continued, "Patients with CRPS have very few options, and CY200 is designed to address that need. Our objective in the UAE was to meet investors and potential partners who take a long-term view of drug development and who understand the opportunity in differentiated clinical-stage assets."
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotechnology company developing novel neuroplastogenic therapies using psychedelics that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The company is also developing a new class of highly novel opioids for the treatment of severe pain while minimizing the risk of both drug abuse and overdose. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management's estimates and forecasts and reflect the current views, assumptions, expectations and opinions of the Company as of the date hereof. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expected, including (i) possible Nasdaq delisting; (ii) failure to obtain stockholder approval for the conversion of the Series C non-voting convertible preferred stock into shares of common stock of the combined company; (iii) risks related to the combined company's ability to manage its operating expenses and its expenses associated with the acquisition; (iv) unexpected costs, charges or expenses resulting from the acquisition; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition; (vi) the uncertainties associated with the combined company's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement and completion of clinical trials, studies and evaluations; (vii) risks related to the inability of the combined company to obtain sufficient additional capital, including the continuation of government funding, to continue to advance these or other product candidates; (viii) failure to achieve the clinical trial milestone for the Milestone Closing; (ix) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating results. These statements are also subject to risks and uncertainties described in Ensysce's most recent annual report on Form 10-K and quarterly report on Form 10-Q and in other filings that it makes with the U.S. Securities and Exchange Commission (the "SEC"), available at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What clinical development step has Ensysce taken for CY200?
Ensysce submitted the protocol for a Phase 2a clinical study of CY200 for Complex Regional Pain Syndrome to the UK Medicines and Healthcare products Regulatory Agency in September 2026.